Market closed

Cardiol Therapeutics/CRDL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Ticker

CRDL
Trading on

Industry

Pharmaceuticals

Headquarters

Oakville, Canada

Employees

-

CRDL Metrics

BasicAdvanced
$137M
Market cap
-
P/E ratio
-$0.33
EPS
0.69
Beta
-
Dividend rate
$137M
0.69
$3.12
$0.66
348K
2.394
2.245
0.928
1.069
-54.15%
-108.43%
12
12.14
-8.223
-6.52%
-19.34%

What the Analysts think about CRDL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.

CRDL Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRDL Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy CRDL

$

Sign up or log in to buy
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cardiol Therapeutics stock?

Cardiol Therapeutics (CRDL) has a market cap of $137M as of October 06, 2024.

What is the P/E ratio for Cardiol Therapeutics stock?

The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of October 06, 2024.

Does Cardiol Therapeutics stock pay dividends?

No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of October 06, 2024.

When is the next Cardiol Therapeutics dividend payment date?

Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.

What is the beta indicator for Cardiol Therapeutics?

Cardiol Therapeutics (CRDL) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.